Plus therapeutics presents positive interim respect-lm phase 1 data for leptomeningeal metastases at 2024 sno/asco cns metastases conference

Respect-lm dosing shows continued feasibility and safety of up to 44 mci of intrathecal rhenium ( 186 re) obisbemeda high absorbed radiation doses, mean circulating tumor cell reductions, and median overall survival of 12 months continue to show clinical promise austin, texas, aug. 12, 2024 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (“plus” or the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, presented data in a podium presentation updating the progress of its respect-lm clinical trial of rhenium (186re) obisbemeda (rhenium nanoliposome, 186rnl) in leptomeningeal disease (lm). the data were presented at the 2024 society for neurooncology (sno)/american society for clinical oncology (asco) cns metastases conference august 8-10, 2024 in denver, colorado.
PSTV Ratings Summary
PSTV Quant Ranking